SINEMET Drug Patent Profile

Which patents cover Sinemet, and when can generic versions of Sinemet launch?

Sinemet is a drug marketed by Organon and Organon Llc and is included in two NDAs.

The generic ingredient in SINEMET is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sinemet

A generic version of SINEMET was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28^th, 1992.

Summary for SINEMET

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	86
Drug Prices:	Drug price information for SINEMET
What excipients (inactive ingredients) are in SINEMET?	SINEMET excipients list
DailyMed Link:	SINEMET at DailyMed

See drug prices for SINEMET

Recent Clinical Trials for SINEMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Julien Bally	PHASE1
University of California, Los Angeles	Phase 1/Phase 2
Laboratorios Andromaco S.A.	Phase 1

See all SINEMET clinical trials

Pharmacology for SINEMET

Drug Class

Aromatic Amino Acid

US Patents and Regulatory Information for SINEMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	SINEMET	carbidopa; levodopa	TABLET;ORAL	017555-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Organon Llc	SINEMET CR	carbidopa; levodopa	TABLET, EXTENDED RELEASE;ORAL	019856-002	Dec 24, 1992		DISCN	Yes	No
Organon	SINEMET	carbidopa; levodopa	TABLET;ORAL	017555-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Expired US Patents for SINEMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	SINEMET	carbidopa; levodopa	TABLET;ORAL	017555-002	Approved Prior to Jan 1, 1982
Organon	SINEMET	carbidopa; levodopa	TABLET;ORAL	017555-002	Approved Prior to Jan 1, 1982
Organon	SINEMET	carbidopa; levodopa	TABLET;ORAL	017555-001	Approved Prior to Jan 1, 1982

EU/EMA Drug Approvals for SINEMET

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amneal Pharma Europe Ltd	Numient	levodopa, carbidopa	EMEA/H/C/002611Symptomatic treatment of adult patients with Parkinson’s disease	Withdrawn	no	no	no	2015-11-19

International Patents for SINEMET

See the table below for patents covering SINEMET around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	951661	PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANOIC ACIDS
Yugoslavia	35110
Yugoslavia	35090

Supplementary Protection Certificates for SINEMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	2390502-9	Sweden		PRODUCT NAME: FOSLEVODOPA/FOSCARBIDOPA; NAT. REG. NO/DATE: MTNR 62386 20220912; FIRST REG.: AT 141371 20220826

SINEMET Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for SINEMET?

SINEMET, a combination of levodopa and carbidopa, treats Parkinson’s disease by replenishing dopamine levels in the brain. It dominates the Parkinson’s therapy market due to its established efficacy and widespread adoption.

Market Size and Growth

• The global Parkinson’s disease treatment market was valued at approximately USD 4.2 billion in 2021.
• Estimated CAGR: 6.3% (2022-2028), driven by rising prevalence and aging populations.
• Sinemet holds an estimated 55-70% market share among levodopa formulations, making it the leading brand globally.

Competitive Landscape

Major competitors include:

• Rytary (carbidopa/levodopa extended-release)
• Duopa (intestinal gel)
• Generic formulations produced by multiple manufacturers following patent expirations.

Sinemet’s legacy and brand recognition sustain its market position over newer, more expensive alternatives. However, patent expirations approaching in the coming years could erode its market share as generics expand.

Regulatory and Patent Environment

• The original patent for Sinemet expired in the U.S. in 2006, initiating a wave of generic competition.
• Current formulations are mostly generic; specific branded versions are often used in cases requiring controlled-release delivery or specific patient needs.
• Ongoing patent litigations, if any, could influence pricing or availability.

Influencing Factors

• Aging demographics: The number of diagnosed Parkinson’s patients increases by approximately 1 million annually worldwide.
• Off-label and combination therapy trends: Growing use of adjunct therapies may influence Sinemet’s market share.
• Manufacturing and supply chain stability: Critical for maintaining market presence, especially in regions with healthcare access issues.

What Is the Financial Trajectory for SINEMET?

Revenue Trends

• Estimated global annual sales: USD 1.2-1.5 billion, with the majority generated in North America and Europe.
• Revenue plateauing in mature markets due to patent expirations and generic penetration.
• Growth projected to decline gradually as generic versions saturate markets.

Pricing and Market Share Dynamics

• Branded Sinemet historically priced significantly higher than generics.
• With increased generic competition, price erosion is expected:
  • Retail price reductions of up to 70-80% have been observed post-patent expiry.
  • Price volatility may impact profit margins for manufacturers holding current patents.

R&D Investment and Pipeline

• Limited R&D focus as the core formulation is established.
• Investigations are ongoing into extended-release and novel delivery systems to improve disease management.
• Potential pipeline developments include formulations aimed at reducing dosing frequency and minimizing side effects.

Market Risks and Opportunities

• Patent cliffs pose risk to revenue streams.
• Emerging markets present opportunity for growth via increased disease diagnosis and healthcare expansion.
• Development of disease-modifying therapies could impact share as treatment paradigms evolve.

Summary of Financial Outlook

Parameter	2021	2022	2023	2024	2025 (Projected)
Market Size (USD billion)	4.2	4.4	4.3	4.1	3.9-4.2
Sinemet Market Share	60%	55%	50%	45%	Declining
Revenue (USD billion)	1.2	1.3	1.2	1.1	Slight decline
Generic Penetration	30%	40%	50%	60%	Increasing

Key Takeaways

• Sinemet's market dominance stems from its established efficacy but faces decline due to patent expiry and generics.
• The global Parkinson’s treatment market grows steadily with aging demographics, yet Sinemet’s revenue trajectory may decline.
• Price erosion and patent expirations threaten profit margins, while emerging markets and innovative formulations offer growth avenues.
• Limited R&D investment suggests minimal innovation in Sinemet’s core formulation ahead.
• Market risks include competition from newer agents and regulatory changes, while opportunities lie in expanding diagnostic rates and pipeline developments.

FAQs

1. When will Sinemet’s patent expire in major markets?
Patent expirations occurred in the U.S. in 2006; other regions experienced similar timelines between 2005-2010. Future patents for extended-release formulations could extend exclusivity.

2. How does the rise of generic versions affect Sinemet’s sales?
Generic competition reduces prices and market share, leading to lower revenue margins and potential sales decline in mature markets.

3. Are there alternative treatments that threaten Sinemet’s market position?
Yes. Newer drugs like Rytary, Duopa, and disease-modifying therapies are alternatives. However, Sinemet remains the first-line due to its efficacy and long clinical track record.

4. What is the outlook for Sinemet in emerging markets?
Growing healthcare infrastructure and rising diagnosis rates support expansion, but affordability and regulatory approval processes pose challenges.

5. Will there be innovation in Sinemet formulations?
Limited pipeline activity exists. Most innovation focuses on extended-release systems or combination therapy delivery, aiming to improve patient compliance and safety.

---

References

[1] MarketWatch, "Global Parkinson’s Disease Treatment Market Size, Share & Trends," 2022.
[2] Grand View Research, "Parkinson’s Disease Market Analysis," 2021.
[3] FDA, "Patent Expirations and Generic Drug Approvals," 2022.